A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC

BackgroundThe current standard approach to the treatment of patients with non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)—sensitizing mutations has been the treatment with a first-generation EGFR-TKIs. While, with resistance develope...

Full description

Bibliographic Details
Main Authors: Yongxing Li, Jianye Yang, Yufen Xu, Ming Zhang, Xiaoping Zhang, Wenyu Chen, Xiaodong Lv
Format: Article
Language:English
Published: AIMS Press 2019-06-01
Series:Mathematical Biosciences and Engineering
Subjects:
Online Access:https://www.aimspress.com/article/10.3934/mbe.2019283?viewType=HTML